Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC

By Chung-Han Lee, MD, PhD, Rana McKay, MD - Last Updated: August 23, 2023

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, and Rana McKay, MD, University of California, San Diego Moores Cancer Center, discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma.

View more ASCO 2023 videos.

Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC

Ajitha Kommalapati, MDASCO 2023 | August 15, 2023

Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.

Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC

Shilpa Gupta, MDASCO 2023 | August 31, 2023

Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.

Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya JindalASCO 2023 | July 28, 2023

Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.

Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.

Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC

Related Posts